A retrospective study for the treatments and prognosis of brain metastases of gynecologic malignancies

A retrospective study for the treatments and prognosis of brain metastases of gynecologic malignancies - KCOG-G1001s

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003542

Enrollment

100

Registered

2010-05-01

Start date

2010-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain metastases of gynecologic malignancies diagnosed with imaging modalities

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients diagnosed as brain metastases of gynecologic malignancies from January, 1995 to December, 2009 Patients with pathologically confirmed gynecologic malignancies

Exclusion criteria

Exclusion criteria: Petients with history of non-gynecologic malignancies Ptients with active non-gynecologic malignancy Choriocarcinoma Petients with history of treatment for central nervous system disease

Design outcomes

Primary

Measure	Time frame
Age at diagnosis Duration from the initial diagnosis to the recurrence Duration from the initial diagnosis to the detection of brain metastases Sites of brain metastases Site and stage of primary disease Pathological diagnosis of primary disease Complication Initial treatment for the primary disease Effects of primary chemotherapy Presence of pulmonary metastases Sites of recurrence Symptoms at recurrence Neurological findings at diagnosis of brain metastases Karnofsky Performance Status (KPS) and Recursive Partitioning Analysis (RPA) Imaging modalities for the diagnosis of brain metastases Numbers, Sites and size of brain metastases Treatment modalities for brain metastases and their therapeutic effects and adverse effects Status of neurologic symptoms after treatments Prognosis Cause of death	—

Measure

Time frame

Age at diagnosis Duration from the initial diagnosis to the recurrence Duration from the initial diagnosis to the detection of brain metastases Sites of brain metastases Site and stage of primary disease Pathological diagnosis of primary disease Complication Initial treatment for the primary disease Effects of primary chemotherapy Presence of pulmonary metastases Sites of recurrence Symptoms at recurrence Neurological findings at diagnosis of brain metastases Karnofsky Performance Status (KPS) and Recursive Partitioning Analysis (RPA) Imaging modalities for the diagnosis of brain metastases Numbers, Sites and size of brain metastases Treatment modalities for brain metastases and their therapeutic effects and adverse effects Status of neurologic symptoms after treatments Prognosis Cause of death

—

Countries

Japan

Outcome results